Upfront Combo Lipid-Lowering Therapy Best for Acute Coronary Syndrome
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
FRIDAY, Sept. 8, 2023 -- For patients with acute coronary syndromes (ACS), an upfront combination lipid-lowering therapy is significantly better than statin monotherapy for all-cause mortality, according to a study published online Sept. 6 in the Journal of the American Heart Association.
Joanna Lewek, M.D., Ph.D., from the Medical University of Lodz in Poland, and colleagues compared statin monotherapy and upfront combination therapy of statin and ezetimibe in a cohort of 38,023 consecutive patients with ACS who were discharged alive from a national, multicenter prospective observational registry. Two groups were analyzed after propensity score matching: statin monotherapy (atorvastatin or rosuvastatin; 768 patients) and upfront combination therapy of statin and ezetimibe (768 patients).
The researchers found that during follow-up, there was a significant difference in mortality between the groups at one (5.9 versus 3.5 percent), two (7.8 versus 4.3 percent), and three (10.2 versus 5.5 percent) years of follow-up, favoring the upfront combination group; the difference was also significant for the overall period. Compared with atorvastatin, rosuvastatin significantly improved prognosis (odds ratio, 0.790). A significant reduction in all-cause mortality was seen with upfront combination therapy versus statin monotherapy (odds ratio, 0.526), with an absolute risk reduction of 4.7 percent after three years.
"We proved, for the first time, that upfront combination lipid-lowering therapy is superior to statin monotherapy for all-cause mortality," the authors write. "It undermines the stepwise approach, confirming the benefit of using the upfront combination strategy in patients with very high cardiovascular disease risk."
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted September 2023
Read this next
Apple Cider Vinegar Beneficial for Overweight, Obese Individuals
WEDNESDAY, March 13, 2024 -- For overweight and obese individuals, apple cider vinegar (ACV) consumption is associated with a significant reduction in anthropometric variables, as...
Dyslipidemia Raising Risk for CVD Among Young American Indians
TUESDAY, March 12, 2024 -- Dyslipidemia is associated with subclinical and clinical cardiovascular disease (CVD) among young American Indians, according to a study published...
2015 to 2021 Saw Marked Rise in PCSK9 Inhibitor Utilization
TUESDAY, March 5, 2024 -- Barriers for proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) use persist for cholesterol management, according to a research letter...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.